Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 8.01Vimta Labs Ltd. demonstrates a very strong financial profile, marked by exceptional profitability, growth, and long-term stability. The company operates with almost no debt, making it highly resilient to economic shifts. Its ability to generate profits from its operations is a standout strength, and it has consistently expanded its revenue and earnings at an impressive rate, indicating a powerful position in the healthcare services market. The primary area of weakness is in operational efficiency. The company is slow to collect cash from customers and does not generate as much revenue as it could from its assets. While the company is investing heavily back into the business for future growth, current returns to shareholders via dividends are low. Overall, Vimta Labs is a financially robust and rapidly growing company, with its main challenge lying in optimizing its day-to-day asset and cash management cycles.
Health Score : 8.01Vimta Labs Ltd. demonstrates a very strong financial profile, marked by exceptional profitability, growth, and long-term stability. The company operates with almost no debt, making it highly resilient to economic shifts. Its ability to generate profits from its operations is a standout strength, and it has consistently expanded its revenue and earnings at an impressive rate, indicating a powerful position in the healthcare services market. The primary area of weakness is in operational efficiency. The company is slow to collect cash from customers and does not generate as much revenue as it could from its assets. While the company is investing heavily back into the business for future growth, current returns to shareholders via dividends are low. Overall, Vimta Labs is a financially robust and rapidly growing company, with its main challenge lying in optimizing its day-to-day asset and cash management cycles.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
33.92
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
50.70
P/B RATIO
6.08
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
N/A
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
0.00
EV/EBITDA RATIO
23.27
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹469.5 as on May 29, 2026.
Growth Score : 10.00The company has demonstrated exceptional growth across the board. It has been highly successful in increasing its revenues, profits, and overall size. This strong growth trajectory is a major positive, indicating robust market demand, effective business strategy, and strong operational execution. This performance suggests a very positive outlook for the company's expansion and future earnings potential, making it a standout in terms of development and market penetration.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.57 | 31.75 | 14.39 | 0 | |
| Operating Profit Growth Rate | 76.67 | 50.94 | 18.75 | -8.42 | |
| Earnings Per Share (EPS) Growth | 212.26 | 93.18 | 16.26 | -14.81 | |
| Asset Growth Rate | 11.38 | 12.04 | 17.92 | 10.5 | |
| Net Income Growth Rate | 200 | 95.24 | 17.07 | -14.58 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vimta Labs Ltd | 8.01 | 50.70 | Neutral | 113.00 | 17.35 | 61.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Vimta Labs Ltd is a leading Indian contract research and testing organization (CRTO) providing comprehensive analytical and clinical research services. It specializes in testing for food, pharmaceuticals, water, environment, and consumer products, alongside offering bioequivalence/bioavailability and preclinical studies. The company is recognized for its extensive accreditations and quality standards.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Vimta Labs Ltd's P/E ratio (TTM) is 33.92, compared to the industry median of 36.13 and large cap median of 35.79.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Vimta Labs Ltd's P/B ratio is 6.08, compared to the industry median of 6.08 and large cap median of 6.08.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Vimta Labs Ltd's P/S ratio is 4.55, compared to the industry median of 5.75 and large cap median of 5.17.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Vimta Labs Ltd's PEG ratio is 1.92.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Vimta Labs Ltd's EV/EBITDA ratio is 23.27.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Vimta Labs Ltd's ROE is 12.85%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Vimta Labs Ltd's ROA is 21.75%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Vimta Labs Ltd's ROCE is 18%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Vimta Labs Ltd's operating margin is 27.36%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Vimta Labs Ltd's net margin is 12.89%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Vimta Labs Ltd's current ratio is 2.39.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Vimta Labs Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Vimta Labs Ltd's interest coverage ratio is 28.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Vimta Labs Ltd's DPS is ₹1.02.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Vimta Labs Ltd's EPS is -14.81.
(Source line: "Ratios as of 29 May 2026, based on last traded price of ₹469.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Vimta Labs was incorporated in 1984 as a private limited company and subsequently became a public limited company in 1990. It commenced commercial operations in 1990, establishing itself as a multidisciplinary contract testing and research organization. Over the decades, Vimta Labs has expanded its service portfolio and infrastructure, acquiring numerous national and international accreditations, solidifying its position as a key player in India's CRTO sector.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Analytical & Clinical Research Services | 100% | Operating Profit |
Dr. S. P. Vasireddi - Chairman & Managing Director: Founder of Vimta Labs, Dr. Vasireddi is a visionary leader with profound expertise in analytical sciences and business management, guiding the company's strategic growth and operational excellence since its inception.
No major recent corporate actions on record.
References
The Vimta Labs Ltd share price today is ₹469.50 on NSE (VIMTALABS), as of 15 Aug 2026.
As of 29 May 2026, Vimta Labs Ltd share price is ₹469.50, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Vimta Labs Ltd's market cap is ₹2,093.97 crore (Small Cap).
Vimta Labs Ltd's current P/E ratio is 33.92, compared to the General Industrials (Capital Goods) sector average of 33.50.
Vimta Labs Ltd's current P/B ratio is 6.08.
Vimta Labs Ltd's current dividend yield is 0.22%. Last dividend of ₹2.00 per share was declared on 10-Aug-2023.
Vimta Labs Ltd's EPS (TTM) is ₹-14.81.
Vimta Labs Ltd is a leading Indian contract research and testing organization (CRTO) providing comprehensive analytical and clinical research services. It specializes in testing for food, pharmaceuticals, water, environment, and consumer products, alongside offering bioequivalence/bioavailability and preclinical studies. The company is recognized for its extensive accreditations and quality standards.
Vimta Labs Ltd is promoted by Dr. S. P. Vasireddi & Family, holding 35.85% as of 29 May 2026.
Vimta Labs Ltd is listed on NSE (VIMTALABS) and BSE (524394). Its next quarterly results are expected on August 2024.
Inventory Turnover Ratio